Almersjö O E, Gustavsson B G, Regårdh C G, Wåhlén P
Acta Pharmacol Toxicol (Copenh). 1980 May;46(5):329-36. doi: 10.1111/j.1600-0773.1980.tb02463.x.
The pharmacokinetic conditions for oral administration of 5-fluorouracil (5-FU) were investigated in 16 patients with malignant liver tumours. The concentration of 5-FU in portal and systemic blood was determined by a microbiologic method every 10 min. during 2 hours after oral or intravenous administration of a standard dose of 250 mg 5-FU ( approximately 4 mg/kg b. wt.) or 15 mg 5-FU/kg b. wt. The drug was rapidly absorbed after oral administration with peak values within 10-30 min. 25% of the lower and 40% of the higher oral dose reached the systemic circulation. The reduction of systemic bio-availability was partly accomplished by a loss in the gastrointestinal tract and partly by extraction by the liver. The hepatic extraction ratio was calculated to 0.56 and 0.26 after the lower and the higher dose respectively indicating a saturable process. The availability of 5-FU was significantly higher in portal blood than in systemic blood after oral administration. The opposite conditions were found after intravenous administration. Thus, oral administration of 5-FU to patients with malignant liver tumours seems rational.
对16例恶性肝肿瘤患者口服5-氟尿嘧啶(5-FU)的药代动力学情况进行了研究。口服或静脉注射标准剂量250mg 5-FU(约4mg/kg体重)或15mg 5-FU/kg体重后,每10分钟用微生物学方法测定门静脉血和全身血中5-FU的浓度,持续2小时。口服给药后药物吸收迅速,峰值出现在10 - 30分钟内。较低口服剂量的25%和较高口服剂量的40%进入体循环。全身生物利用度的降低部分是由于胃肠道损失,部分是由于肝脏摄取。较低剂量和较高剂量后肝脏摄取率分别计算为0.56和0.26,表明存在饱和过程。口服给药后门静脉血中5-FU的可用性显著高于全身血。静脉注射后情况相反。因此,对恶性肝肿瘤患者口服5-FU似乎是合理的。